Rani Therapeutics Holdings Inc
RANI
查看详细走势图
1.220USD
+0.120+10.91%
收盘 02/06, 16:00（美东）报价延迟15分钟
58.49M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+10.91%
5天
+0.83%
1月
-12.23%
6月
+128.89%
今年开始到现在
-9.63%
1年
-19.74%
查看详细走势图
TradingKey Rani Therapeutics Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Rani Therapeutics Holdings Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名147/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.25。中期看，股价处于下降通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Rani Therapeutics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Rani Therapeutics Holdings Inc亮点
亮点风险
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
业绩增长期
公司处于发展阶段，最新年度总收入1.03M美元
估值合理
公司最新PE估值-1.58，处于3年历史合理位
机构加仓
最新机构持股28.84M股，环比增加42.37%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值5.44K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.10
分析师目标
根据
3
位分析师
买入
评级
9.250
目标均价
+677.31%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Rani Therapeutics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Rani Therapeutics Holdings Inc简介
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
公司代码RANI
公司Rani Therapeutics Holdings Inc
CEOImran (Talat)
网址https://www.ranitherapeutics.com/
相关品种
